JWJeanine P. Wiener-Kronish

Jeanine P. Wiener-Kronish

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeanine P. Wiener-Kronish has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Adam A. Dalia

    Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston

    1 shared publication
  • Ala Nozari

    1 shared publication
  • Amua Carmago

    Department of Anesthesia and Perioperative Care, University of California, San Francisco, California,1 Department of Medicine, Lung Biology Center, University of California, San Francisco, California,2 Biogen Idec, Inc., Cambridge, Massachusetts,3 Cancer Hospital, Fudan University, Shanghai 200032, People's Republic of China4

    1 shared publication
  • Dara Frank

    Medical College of Wisconsin

    1 shared publication
  • Dusan Hanidziar

    Massachusetts General Hospital, Boston, Massachusetts

    1 shared publication
  • Edward A. Bittner

    Harvard Medical School

    1 shared publication

Latest Publications

  • Perioperative Risk Assessment and Avoiding Overuse of Anesthesia Care for Routine Cataract Surgery

    by Adam A. Dalia, Timothy Houle, Jeanine Wiener-Kronish

    To the Editor The retrospective observational cohort study by Dr Perumal and colleagues1 evaluated a 5% sample of Medicare beneficiaries undergoing cataract surgery; the authors defined anesthesia care as the presence or absence of anesthesia personnel. These authors concluded that anesthesia care was not associated with lower perioperative complication rates among patients undergoing cataract surgery, and that the rate of complications after cataract surgery was less than for other procedures with lower rates of anesthesia care.


  • Open Access

    Remote Surveillance Technologies: Realizing the Aim of Right Patient, Right Data, Right Time

    by Kyan C. Safavi, William Driscoll, Jeanine P. Wiener-Kronish

    The convergence of multiple recent developments in health care information technology and monitoring devices has made possible the creation of remote patient surveillance systems that increase the timeliness and quality of patient care. More convenient, less invasive monitoring devices, including patches, wearables, and biosensors, now allow for continuous physiological data to be gleaned from patients in a variety of care settings across the perioperative experience. These data can be bound into a single data repository, creating so-called data lakes. The high volume and diversity of data in these repositories must be processed into standard formats that can be queried in real time. These data can then be used by sophisticated prediction algorithms currently under development, enabling the early recognition of patterns of clinical deterioration otherwise undetectable to humans. Improved predictions can reduce alarm fatigue. In addition, data are now automatically queriable on a real-time basis such that they can be fed back to clinicians in a time frame that allows for meaningful intervention. These advancements are key components of successful remote surveillance systems. Anesthesiologists have the opportunity to be at the forefront of remote surveillance in the care they provide in the operating room, postanesthesia care unit, and intensive care unit, while also expanding their scope to include high-risk preoperative and postoperative patients on the general care wards. These systems hold the promise of enabling anesthesiologists to detect and intervene upon changes in the clinical status of the patient before adverse events have occurred. Importantly, however, significant barriers still exist to the effective deployment of these technologies and their study in impacting patient outcomes. Studies demonstrating the impact of remote surveillance on patient outcomes are limited. Critical to the impact of the technology are strategies of implementation, including who should receive and respond to alerts and how they should respond. Moreover, the lack of cost-effectiveness data and the uncertainty of whether clinical activities surrounding these technologies will be financially reimbursed remain significant challenges to future scale and sustainability. This narrative review will discuss the evolving technical components of remote surveillance systems, the clinical use cases relevant to the anesthesiologist’s practice, the existing evidence for their impact on patients, the barriers that exist to their effective implementation and study, and important considerations regarding sustainability and cost-effectiveness.


  • Open Access

    The Complexity and Challenges of Intensive Care Unit Admissions and Discharges

    by Kyan Safavi, Jeanine Wiener-Kronish, Dusan Hanidziar

    Patients admitted to the intensive care unit (ICU) are heterogeneous in their underlying illnesses, comorbidities, and requirements for either invasive or nearl


  • Open Access

    Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review

    by Teiji Sawa, Masaru Shimizu, Kiyoshi Moriyama, Jeanine P Wiener-Kronish

    Pseudomonas aeruginosa uses a complex type III secretion system to inject the toxins ExoS, ExoT, ExoU, and ExoY into the cytosol of target eukaryotic cells. This system is regulated by the exoenzyme S regulon and includes the transcriptional activator ExsA. Of the four toxins, ExoU is characterized as the major virulence factor responsible for alveolar epithelial injury in patients with P. aeruginosa pneumonia. Virulent strains of P. aeruginosa possess the exoU gene, whereas non-virulent strains lack this particular gene. The mechanism of virulence for the exoU + genotype relies on the presence of a pathogenic gene cluster (PAPI-2) encoding exoU and its chaperone, spcU. The ExoU toxin has a patatin-like phospholipase domain in its N-terminal, exhibits phospholipase A2 activity, and requires a eukaryotic cell factor for activation. The C-terminal of ExoU has a ubiquitinylation mechanism of activation. This probably induces a structural change in enzymatic active sites required for phospholipase A2 activity. In P. aeruginosa clinical isolates, the exoU + genotype correlates with a fluoroquinolone resistance phenotype. Additionally, poor clinical outcomes have been observed in patients with pneumonia caused by exoU + -fluoroquinolone-resistant isolates. Therefore, the potential exists to improve clinical outcomes in patients with P. aeruginosa pneumonia by identifying virulent and antimicrobial drug-resistant strains through exoU genotyping or ExoU protein phenotyping or both.


  • The History of the Anesthetist as a Perioperative Physician

    by Marlene R. Meyer, Jeanine P. Wiener-Kronish

  • Open Access

    Treating bacterial virulence systems: we are not there yet

    by Yvonne J. Huang, Edward A. Bittner, Dara Frank, Jeanine Wiener-Kronish

  • Therapies against Virulence Products ofStaphylococcus aureusandPseudomonas aeruginosa

    by Jeanine P Wiener-Kronish, Jean-Francois Pittet

    Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa are key pathogens in hospitals (particularly intensive care units), in long-term care facilities, and in outpatients with specific comorbidities and risk factors. Both MRSA and P. aeruginosa display resistance to a wide array of antibiotics. Further, both bacteria contain a variety of virulence products or systems that make it difficult to treat associated infections. Within the past several years, community-acquired MRSA containing virulence factors [particularly the Panton-Valentine leukocidin (PVL) gene] has emerged globally. Given the limited number of novel antibiotics to treat antibiotic-resistant organisms, there is growing interest in treating bacterial infections by targeting specific virulence products or systems. This article reviews potential therapeutic targets in the virulence systems of these two bacteria that are responsible for a large number of serious infections in critically ill patients.


  • Mechanisms of bacterial virulence in pulmonary infections

    by Samuel M Moskowitz, Jeanine P Wiener-Kronish

    Purpose of review To consider the relevance to severe human lung infections of recently discovered virulence mechanisms of Staphylococcus aureus and Francisella tularensis. Recent findings S. aureus has long been considered an opportunistic pathogen. However, due to the emergence of community-acquired methicillin-resistant S. aureus (CA-MRSA) strains that can readily infect and kill normal hosts, S. aureus must now be considered a potentially virulent pathogen. The evolution of S. aureus from an organism associated with asymptomatic nasopharyngeal colonization to one associated with community-acquired lethal infections may reflect horizontal acquisition of bacterial genes that enable efficient spread, aggressive host invasion, and effective immune evasion. Alleviating the burden of staphylococcal disease will require better understanding of host susceptibility and of staphylococcal virulence and antibiotic resistance. In contrast to the rapidly evolving staphylococcal virulence strategy, recent genomic analysis of F. tularensis has revealed a small set of bacterial genes associated with the marked virulence of its North American subspecies. This suggests that a relatively stable strategy of immune evasion underlies this pathogen's ability to establish serious life-threatening lung infections from a very small inoculum. Summary Understanding bacterial pathogenesis will require additional research into both host susceptibility factors and bacterial virulence mechanisms, including horizontal gene transfer. Refinements in the molecular detection of bacteria in the clinical setting, as well as whole genome analysis of both pathogens and patients, are expected to aid in the understanding of bacterial-induced lung injury.